Online inquiry

IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11641MR)

This product GTTS-WQ11641MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LAG3&PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002286.6; NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902; 5133
UniProt ID P18627; Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11641MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14610MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ13299MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ1685MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ6226MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ2654MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ9012MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ8727MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ13820MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-10987
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW